biotech
African Women Test Anti-HIV Gel in Phase 3 Clinical Trials
Filed in archive Drugs, Vaccines and Therapeutics by ruth on February 11, 2006
BlogPicture

More than 6,000 women in South Africa has been recruited for the Phase 3 clinical trials of the microbicide gel against AIDS called Carraguard. According to the Population Council:
Carraguard® (formerly known as PC-515) is the Population Council's lead candidate microbicide, a gel whose active pharmaceutical ingredient is made from carrageenan, a substance derived from seaweed. Carrageenan is inexpensive and stable and has been used for hundreds of years as a thickener in foods and as an emulsifier in topical creams and lotions.


Previous in vitro and in vivo trials have shown Carraguard to prevent HIV transmission, by lining the vaginal mucosa, thereby blocking the HIV virus from entering the cells.

This Phase 3 clinical trials are conducted to confirm that Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and that the gel is safe for vaginal use. The study is expected to be concluded early 2007.

Source: Womens E-news, Photo: PopCouncil

Permalink: African Women Test Anti-HIV Gel in Phase 3 Clinical Trials
Tags: HIV  microbicide  biotech  phase  trials  phase+clinical  clinical+trials  women+test 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/15333
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for African Women Test Anti-HIV Gel in Phase 3 Clinical Trials:

  • Currently 6.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.00 out of 3 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!